MedTrace Logo

Clinical Trials

NCT05063552 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
430 participants

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2023-03-13
Completion:
2027-12-15
Conditions
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma
  • Metastatic Laryngeal Squamous Cell Carcinoma
  • Metastatic Lip and Oral Cavity Carcinoma
  • Metastatic Nasal Cavity Squamous Cell Carcinoma
  • Metastatic Nasopharyngeal Squamous Cell Carcinoma
  • Metastatic Pharyngeal Squamous Cell Carcinoma
  • Metastatic Sinonasal Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
  • Recurrent Nasopharyngeal Squamous Cell Carcinoma
  • Recurrent Pharyngeal Squamous Cell Carcinoma
  • Recurrent Sinonasal Squamous Cell Carcinoma
  • Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage IV Hypopharyngeal Carcinoma AJCC v8
  • Stage IV Laryngeal Cancer AJCC v8
  • Stage IV Lip and Oral Cavity Cancer AJCC v8
  • Stage IV Nasopharyngeal Carcinoma AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IV Sinonasal Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
NCT05058651 | SUSPENDED | PHASE2/PHASE3
189 participants

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-06-28
Completion:
2028-10-01
Conditions
  • Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Metastatic Extrapulmonary Neuroendocrine Carcinoma
  • Recurrent Extrapulmonary Neuroendocrine Carcinoma
  • Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
  • OTHER
No Results Yet
NCT05045820 | ACTIVE_NOT_RECRUITING | NA
106 participants

Integrative Medicine in Pain Management in Sickle Cell Disease

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-06-29
Completion:
2025-06-20
Conditions
  • Sickle Cell Disease
  • Pain
  • Acupuncture
  • Quantitative Sensory Testing
  • Magnetic Resonance Imaging
  • Circulating Biomarkers
  • Electroencephalography
  • Functional Near-infrared Spectroscopy
Interventions
  • DEVICE
No Results Yet
NCT05019716 | RECRUITING | PHASE1/PHASE2
36 participants

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-07-13
Completion:
2027-06-07
Conditions
  • Advanced NUT Carcinoma
  • Metastatic NUT Carcinoma
  • Unresectable NUT Carcinoma
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04996875 | RECRUITING | PHASE2
140 participants

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-11-09
Completion:
2025-09-19
Conditions
  • Advanced Systemic Mastocytosis (AdvSM)
  • SM With an Associated Hematologic Neoplasm (SM-AHN)
  • Mast Cell Leukemia (MCL)
  • Aggressive Systemic Mastocytosis (ASM)
Interventions
  • DRUG
No Results Yet
NCT04981509 | RECRUITING | PHASE2
65 participants

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-06-10
Completion:
2027-12-31
Conditions
  • Hereditary Leiomyomatosis and Renal Cell Carcinoma
  • Papillary Renal Cell Carcinoma
  • Renal Cell Carcinoma
  • Sporadic Papillary Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
NCT04963153 | ACTIVE_NOT_RECRUITING | PHASE1
24 participants

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2022-07-07
Completion:
2026-12-01
Conditions
  • Locally Advanced Bladder Urothelial Carcinoma
  • Locally Advanced Renal Pelvis Urothelial Carcinoma
  • Locally Advanced Ureter Urothelial Carcinoma
  • Locally Advanced Urethral Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Renal Pelvis Urothelial Carcinoma
  • Metastatic Ureter Urothelial Carcinoma
  • Metastatic Urethral Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Recurrent Bladder Urothelial Carcinoma
  • Recurrent Renal Pelvis Urothelial Carcinoma
  • Recurrent Ureter Urothelial Carcinoma
  • Recurrent Urethral Urothelial Carcinoma
  • Recurrent Urothelial Carcinoma
  • Stage IIIB Bladder Cancer AJCC v8
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Renal Pelvis Cancer AJCC v8
  • Stage IV Ureter Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04816006 | RECRUITING | NA
160 participants

Breast Cancer, Reasoning, and Activity Intervention

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2024-02-22
Completion:
2028-07-31
Conditions
  • Breast Cancer
  • Breast Neoplasms
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Cancer-related Cognitive Dysfunction
Interventions
  • BEHAVIORAL
  • OTHER
No Results Yet
NCT04763681 | COMPLETED | NA
54 participants

Couple HOPES and COVID-19

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-01-01
Completion:
2024-01-31
Conditions
  • Posttraumatic Stress Disorder
Interventions
  • BEHAVIORAL
No Results Yet
NCT04671667 | RECRUITING | PHASE2
188 participants

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-04-27
Completion:
2029-06-30
Conditions
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Oral Cavity Squamous Cell Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
  • DRUG
  • PROCEDURE
  • RADIATION
  • BIOLOGICAL
No Results Yet
NCT04640623 | ACTIVE_NOT_RECRUITING | PHASE2
220 participants

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-12-18
Completion:
2025-07-03
Conditions
  • Urinary Bladder Neoplasms
Interventions
  • DRUG
  • BIOLOGICAL
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page